# A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

> clinical trial · VERIFIED · 2026-07-31

Status: ACTIVE_NOT_RECRUITING · Sponsor: Bristol-Myers Squibb · Condition: Hepatocellular Carcinoma

- Company: Bristol-Myers Squibb
- Sector: Hepatocellular Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT03383458

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.